Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Abstract Text:

Seh Jong Park,In Keun Choi,Hee Yun Seo,Hwa Jung Sung,Kyong Hwa Park,Seok Jin Kim,Sang Cheul Oh,Jae Hong Seo,Chul Won Choi,Byung Soo Kim,Sang Won Shin,Yeul Hong Kim,Jun Suk Kim,Seh Jong Park,In Keun Choi,Hee Yun Seo,Hwa Jung Sung,Kyong Hwa Park,Seok Jin Kim,Sang Cheul Oh,Jae Hong Seo,Chul Won Choi,Byung Soo Kim,Sang Won Shin,Yeul Hong Kim,Jun Suk Kim,

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Publishing Authors By Initials

SJ Park,IK Choi,HY Seo,HJ Sung,KH Park,SJ Kim,SC Oh,JH Seo,CW Choi,BS Kim,SW Shin,YH Kim,JS Kim,SJ Park,IK Choi,HY Seo,HJ Sung,KH Park,SJ Kim,SC Oh,JH Seo,CW Choi,BS Kim,SW Shin,YH Kim,JS Kim,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Acta haematologica

VOLUME: 118

Page Numbers: 219-21

Journal Abbreviation: Acta Haematol.

ISSN: 1421-9662

DAY: 29

MONTH: 11

YEAR: 2007

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 141053

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.

AFFILIATION: Department of Internal Medicine, Division of Hematology/Oncology, College of Medicine, Korea University, Seoul, Korea.

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Haematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area Related Publications

• Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.
• Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas.
• Advanced capabilities for future light sources.
• Aging of the population and the subsequent increase in the mistreatment of the elderly in Korea.
• Alkali-catalyzed beta-elimination of periodate-oxidized glycans: a novel method of chemical deglycosylation of mucin gene products in paraffin embedded sections.
• Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence.
• Basic fibroblast growth factor-induced translocation of p21-activated kinase to the membrane is independent of phospholipase C-gamma1 in the differentiation of PC12 cells.
• Biological properties and expression of mucins in 5-fluorouracil resistant HT29 human colon cancer cells.
• Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
• Chromosomal clustering of muscle-expressed genes in Caenorhabditis elegans.
• Drynariae Rhizoma promotes osteoblast differentiation and mineralization in MC3T3-E1 cells through regulation of bone morphogenetic protein-2, alkaline phosphatase, type I collagen and collagenase-1.
• Elderly Women's Grief in Korea.
• Expression of MUC2, MUC5AC and MUC6 apomucins in carcinoma, dysplasia and non-dysplastic epithelia of the gallbladder.
• Goblet cell-specific expression mediated by the MUC2 mucin gene promoter in the intestine of transgenic mice.
• Identification and characterization of the MUC2 (human intestinal mucin) gene 5'-flanking region: promoter activity in cultured cells.
• Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma.
• Induction of mucin gene expression in middle ear of rats by tumor necrosis factor-alpha: potential cause for mucoid otitis media.
• Initiation of transcription of the MUC3A human intestinal mucin from a TATA-less promoter and comparison with the MUC3B amino terminus.
• MUC3 human intestinal mucin. Analysis of gene structure, the carboxyl terminus, and a novel upstream repetitive region.
• Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells.
• Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor.
• Monoclonal antibodies against partially deglycosylated colon cancer mucin that recognize Tn antigen.
• Mouse intestinal goblet cells expressing SV40 T antigen directed by the MUC2 mucin gene promoter undergo apoptosis upon migration to the villi.
• Optical design of the U7 undulator beamline at the Pohang Light Source.
• Phorbol 12-myristate 13-acetate induces alteration in mucin gene expression and biological properties of colon cancer cells.
• Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B.
• Stent-graft placement in a traumatic internal carotid-internal jugular fistula and pseudoaneurysm.
• Stereotactic aspiration of intracerebral haematoma: significance of surgical timing and haematoma volume reduction.
• Study of the aging perception.
• The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42.